OssDsign AB (publ) publishes year-end report 2024 
Strategic transformation completed with proven scalability
2024-12-18Extraordinary General Meeting held in OssDsign AB 
Today, an extraordinary general meeting was held in OssDsign AB (publ). Below is a summary of the resolutions adopted at the extraordinary general meeting (in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.ossdsign.com).
2024-11-29Notice to attend the extraordinary general meeting in OssDsign AB 
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the extraordinary general meeting at 10:00 am on Wednesday 18 December 2024 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting.
2024-11-12OssDsign AB (publ) publishes Q3 2024 Interim Report and raises guidance on gross margin 
2024-08-20
OssDsign AB (publ) publishes Q2 2024 Interim Report 
Reaching milestone in orthobiologics sales
2024-06-25Annual General Meeting held in OssDsign AB 
Today, the annual general meeting of 2024 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.ossdsign.com, and supplemented by a press release published on 24 June 2024).
2024-06-04OssDsign publishes Annual Report 2023 
OssDsign AB (publ) announces that the Annual Report for 2023 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also attached to this press release.
2024-05-24NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB 
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 am on Tuesday 25 June 2024 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting.
2024-05-16Change of financial calendar 
2024-05-14
OssDsign AB (publ) publishes Q1 2024 interim report 
We have successfully entered a new era as a pure play orthobiologics company
2024-04-02OssDsign awarded long-term agreement with Premier, Inc. 
Uppsala, Sweden, April 2 – OssDsign AB (publ.) today announces that the company has been awarded a new group purchasing (GPO) agreement for Bone and Bone Substitute Implantable Products with Premier, Inc., a leading U.S. healthcare improvement company uniting an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. The agreement is for a period of three years.
2024-02-06OssDsign AB (publ) publishes year-end report 2023 
Exceptional sales growth for OssDsign Catalyst confirms the value of our strategy shift
2024-01-09OssDsign reports exceptional data from the clinical study TOP FUSION 
Uppsala, January 9, 2024. OssDsign AB (publ.) today announces that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 % spinal fusion rate at 12 months as assessed with CT by independent radiological review from Medical Metrics Inc. after surgery with the novel nanosynthetic bone graft OssDsign Catalyst.
2023-12-06OssDsign’s revenues for the fourth quarter of 2023 are expected to exceed market estimates 
OssDsign AB (publ.) today announces that the company expects its revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October – November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the orthobiologics franchise and some extraordinary orders from a large hospital system.
2023-11-30SEB Venture Capital has sold its holding in OssDsign 
Uppsala, November 30, 2023. OssDsign AB (publ) today announced that SEB Venture Capital has sold its entire holding of about 7.44 million shares, corresponding to approximately 7.6 % of the shares in OssDsign.
2023-11-30OssDsign changes Certified Adviser to Carnegie Investment Bank AB (publ) 
OssDsign AB (publ) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB.
2023-11-21OssDsign AB (publ) publishes Q3 2023 Interim Report 
A new era with OssDsign as a pure play orthobiologics company
2023-10-16Extraordinary General Meeting held in OssDsign AB 
Today an extraordinary general meeting was held in OssDsign AB (publ) (the “Company”). Below is a summary of the resolutions passed at the general meeting (all in accordance with the proposals presented in the notice to attend the general meeting kept available at the Company’s website www.ossdsign.com).
2023-09-27Notice to attend the extraordinary general meeting in OssDsign AB 
The shareholders in OssDsign AB, reg. no. 556841-7546 (the “Company”), are hereby given notice to attend the extraordinary general meeting at 10:00 am on Monday 16 October 2023 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting.
2023-09-26OssDsign has carried out a directed share issue of approximately SEK 150 million 
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. 26 SEPTEMBER 2023, 22:30 CEST OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue of 26,315,790 shares at a subscription price of SEK 5.7 per share (the “Directed Issue”), through which the Company receives approximately SEK 150 million before deduction of transaction costs. The subscription price was determined based on an accelerated book-building procedure lead by Carnegie Investment Bank AB (publ) (“Carnegie”).
2023-09-26OssDsign explores the conditions to carry out a directed share issue 
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. 26 SEPTEMBER 2023, 17:32 CEST OssDsign AB (publ) (”OssDsign” or the ”Company”) intends to explore the conditions to carry out a directed share issue corresponding to approximately SEK 150 million through an accelerated bookbuilding procedure to Swedish and international institutional investors (the “Directed Issue”), starting immediately. OssDsign has engaged Carnegie Investment Bank AB (publ) (“Carnegie”) to act as Sole Bookrunner in connection with the Directed Issue.
2023-09-26OssDsign announces strategic shift to become a pure play orthobiologics company 
Uppsala, September 26, 2023, 17:31 CEST. OssDsign AB (publ) today announced a strategic shift to focus its operations on the orthobiologics business in the U.S, in order to increase shareholder value. The new strategy means that OssDsign will become a pure play orthobiologics company focusing on the nanosynthetic bone graft OssDsign Catalyst, an off-the-shelf product characterized by high scalability and high gross margins at 90 percent or above. All activities pertaining to the company’s patient-specific cranial implant business will be discontinued in a responsible manner by the end of December 2023, resulting in a substantial cost base reduction going forward. As a result, the future capital requirement ahead of becoming cash flow positive will be significantly decreased. Based on the revised strategy, OssDsign’s financial target is to reach sales of SEK 150-200 million in the medium-term, at which point the company also expects to become cash flow positive.
2023-08-22OssDsign AB (publ) publishes Q2 2023 Interim Report 
Bone graft now the biggest franchise.
2023-05-31Annual General Meeting held in OssDsign AB 
Today, the annual general meeting of 2023 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.ossdsign.com).
2023-05-23OssDsign AB (publ) publishes Q1 2023 Interim Report 
Sustainable and accelerating growth